Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

19.50USD
4:00pm EDT
Change (% chg)

$0.34 (+1.77%)
Prev Close
$19.16
Open
$19.23
Day's High
$19.91
Day's Low
$19.07
Volume
299,129
Avg. Vol
632,512
52-wk High
$24.88
52-wk Low
$11.42

Latest Key Developments (Source: Significant Developments)

Nektar Therapeutics reports Q1 revenue $24.7 million
Tuesday, 9 May 2017 04:10pm EDT 

May 9 (Reuters) - Nektar Therapeutics :Nektar Therapeutics reports financial results for the first quarter of 2017.Q1 loss per share $0.42.Q1 revenue $24.7 million versus I/B/E/S view $26.8 million.Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in Phase 3 summit-07 study in chronic pain
Monday, 20 Mar 2017 07:30am EDT 

Nektar Therapeutics : Nektar Therapeutics says NKTR-181, an opioid analgesic, meets primary and secondary endpoints in phase 3 summit-07 study in chronic pain . Nektar therapeutics says NKTR-181 significantly reduced pain in patients with moderate to severe chronic low back pain .FDA has granted investigational NKTR-181 fast track designation for the treatment of moderate to severe chronic pain.  Full Article

Nektar Therapeutics Q4 loss per share $0.28
Wednesday, 1 Mar 2017 04:10pm EST 

Nektar Therapeutics : Nektar Therapeutics reports fourth quarter and year-end 2016 financial results . Q4 loss per share $0.28 . Q4 revenue $37.5 million versus I/B/E/S view $40.7 million .Q4 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Nektar Therapeutics reports financial results for Q3
Thursday, 3 Nov 2016 04:10pm EDT 

Nektar Therapeutics : Nektar Therapeutics reports financial results for the third quarter of 2016 . Q3 loss per share $0.32 . Q3 revenue $36.3 million versus I/B/E/S view $32.9 million .Q3 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.  Full Article

Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration
Tuesday, 27 Sep 2016 06:59am EDT 

Bristol-myers Squibb Co : Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214 . Says Bristol-Myers Squibb and Nektar will equally share costs of combined therapy trials . Myers Squibb co - an initial dose-escalation trial is underway with Opdivo and NKTR-214 . Nektar will maintain its global commercial rights to NKTR-214 .Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214.  Full Article

Nektar Therapeutics reports Q2 loss per share $0.36
Wednesday, 3 Aug 2016 04:15pm EDT 

Nektar Therapeutics : Nektar Therapeutics reports financial results for the second quarter of 2016 . Q2 revenue $32.8 million versus I/B/E/S view $30.5 million . Q2 loss per share $0.36 .Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Nektar says co may pay Daiichi $12.5 mln termination payment
Wednesday, 1 Jun 2016 08:23am EDT 

Nektar :In case of pre-conditional approval termination of deal, nektar would be obligated to pay daiichi a $12.5 million termination payment - sec filing.  Full Article

BRIEF-Nektar Therapeutics, Daiichi Sankyo Europe sign licensing deal for breast cancer drug
Wednesday, 1 Jun 2016 08:15am EDT 

Corrects to add dropped words in the second bullet.Nektar Therapeutics : Nektar Therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments . Nektar Therapeutics says also entitled to significant double-digit royalties on net sales in Europe . Plans to submit an MAA filing in June 2016 seeking conditional approval from EMA for use of Onzeald .Nektar Therapeutics and Daiichi Sankyo Europe GmbH sign European licensing agreement for Onzeald(TM) (Etirinotecan Pegol), an investigational drug candidate being developed to treat patients with advanced breast cancer and brain metastases.  Full Article

Nektar Therapeutics and Daiichi Sankyo Europe sign European licensing agreement for onzeald experimental treatment for breast cancer and brain metastases
Wednesday, 1 Jun 2016 08:15am EDT 

Nektar Therapeutics Says Also Entitled To Significant Double : Nektar therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments . Digit royalties on net sales in europe . Plans to submit an maa filing in june 2016 seeking conditional approval from ema for use of onzeald .Nektar therapeutics and daiichi sankyo europe gmbh sign european licensing agreement for onzeald(tm) (etirinotecan pegol), an investigational drug candidate being developed to treat patients with advanced breast cancer and brain metastases.  Full Article

Nektar Therapeutics closes direct private placement with TPG Special Situations Partners
Tuesday, 6 Oct 2015 08:45am EDT 

Nektar Therapeutics:Closes direct private placement of $250 mln of 7.75% senior secured notes due in 2020.  Full Article

More From Around the Web

BRIEF-Nektar presents findings from two phase 1 clinical studies of NKTR-214

* Presented new findings from two phase 1 clinical studies of NKTR-214, nektar's lead immuno-oncology candidate